Remdesivir-Induced Bradycardia.

Authors

• Sai Gautham Kanagala
• Hardeep Dholiya
• Poonam Jhajj
• Meet A Patel
• Vasu Gupta
• Sachin Gupta
• Shiau-Ing Wu
• Rohit Jain

Publication/Presentation Date

3-1-2023

Abstract

Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because it curbs the viral load expansion. Among patients hospitalized as a result of lower respiratory tract infection, remdesivir proved to improve recovery time; however, remdesivir also can induce significant cytotoxic effects on cardiac myocytes. In this narrative review, we discuss the pathophysiological mechanism of remdesivir-induced bradycardia and diagnostic and management strategies for these patients. We conclude that further research is necessary to understand better the mechanism of bradycardia in coronavirus disease 2019 patients with or without cardiovascular disorder treated with remdesivir.

Volume

116

Issue

3

First Page

317

Last Page

320

ISSN

1541-8243

Published In/Presented At

Kanagala, S. G., Dholiya, H., Jhajj, P., Patel, M. A., Gupta, V., Gupta, S., Wu, S. I., & Jain, R. (2023). Remdesivir-Induced Bradycardia. Southern medical journal, 116(3), 317–320. https://doi.org/10.14423/SMJ.0000000000001519

Disciplines

Medicine and Health Sciences

PubMedID

36863055

Department(s)

Fellows and Residents

Document Type

Article